Business
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
LOS ANGELES, Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"LOS ANGELES, Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September:\nCiti's 17th Annual BioPharma Conference, September 7-8, 2022, in Boston, MAMorgan Stanley's 20th Annual Global Healthcare Conference, September 12-14, 2022, in New York, NY Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will take part in a 30-minute fireside chat on Wednesday, September 14th at 2:55 pm ETA live webcast of the fireside chat will be available on the Investors & News page of the Company's websiteH.C. Wainwright's 24th Annual Global Investment Conference, September 12-14, 2022, in New York, NY A pre-recorded presentation will be available on the Investors & News page of the Company's website on Monday, September 12 at 7:00 am ETLadenburg Thalmann's 2022 Healthcare Conference, September 29, 2022, in New York, NY Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will give a brief presentation followed by an analyst-led fireside chat from 9:00 am – 9:25 am ETA live webcast of the presentation will be available on the Investors & News page of the Company's websiteReplays of webcasts will be available for approximately 30 days following each presentation.\nAbout Aadi Bioscience \nAadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022, Aadi announced the commercial launch of FYARRO in this indication.\nBased on exploratory data from AMPECT, a registrational study supporting approval in advanced malignant PEComa, and following a pre-IND meeting with the FDA, ...